Skip to content
DataLookout
Menu

NCT06533644

A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer

StatusActive, Not Recruiting
PhasePhase 2
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

Version history last read from ClinicalTrials.gov on Aug 30, 2026. The record was updated there on Nov 20, 2026; versions filed since then are not listed here yet.

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Enrollment closed, study ongoing
  2. Minor Trial sites expanded: 19 → 23 locationsv11
  3. Notable Eligibility criteria expanded, about 223 words
    • Primary and study completion pushed from Dec 14, 2027 to Apr 14, 2028
    • Enrollment increased: 70 → 91 participants
    • Trial sites expanded: 9 → 19 locations
    v10
  4. Minor Study sites: 5 to 9v9
  5. Minor Study sites revised (5)v8
Show 6 earlier versionsHide 6 earlier versions
  1. Minor Study sites: 3 to 5
    • Start date changed from estimate of May 2025 to May 29, 2025
    v7
  2. Notable Start date: Mar 2025 to May 2025
    • Study sites: 2 to 3
    v6
  3. Notable Phase: Phase 1 to Phase 2v5 Show 6 more changesShow less
    • Enrollment target: 28 to 70
    • Eligibility criteria expanded, about 38 words
    • Primary endpoints: 4 to 5
    • Interventions: SV-102 (Drug) to Partial Oncolysis (Procedure), SV-102 (Drug)
    • Secondary endpoints revised (16)
    • Study arms: 4 to 5
  4. Minor Study sites: 1 to 2
    • Start date: Jan 2025 to Mar 2025
    v4
  5. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Nov 2024 to Jan 2025
    • Study sites: 0 to 1
    v3
  6. Notable Start date: Sep 15, 2024 to Nov 2024
    • Study title revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Treatment-Emergent Adverse Events (TEAEs), Serious TEAEs and Immune-related Adverse Reactions (imARs)
Timeframe: Up to 2 years
Maximum Tolerated Dose
Timeframe: Up to 48 weeks
Optimal Biologic Dose (OBD)
Timeframe: Up to 48 weeks
Recommended Phase 2 Dose (RP2D)
Timeframe: Up to 48 weeks
Objective Response Rate (ORR)
Timeframe: Up to 2 years

Secondary (16)

Duration of Response
Radiographic Progression-Free Survival (rPFS) per RECIST v1.1 and Prostate Cancer Working Group 3 (PCWG3)
Progression-Free Survival (PFS)
Overall survival (OS)
Trough Concentration (Ctrough) of SV-102
Show 11 moreShow less
Area Under the Concentration Time Curve From Time 0 to the Time t (AUC0-t) of SV-102
Area Under the Concentration Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of SV-102
Maximum Observed Plasma Concentration (Cmax) of SV-102
Last Observed (Quantifiable) Concentration (Clast) of SV-102
Time to Reach the Maximum Plasma Concentration (Tmax) of SV-102
Time of Last Measurable Concentration (Tlast) of SV-102
Apparent Terminal Elimination Half-life (T1/2) of SV-102
Apparent Total Body Clearance (CL/F) of SV-102
Volume of Distribution (Vd) of SV-102
Number of Participants With Any Device Constituent Failures/Malfunctions
Number of Participants With Anti-drug Antibodies (ADA)

Arms and interventions

Part 1 - Dose Escalation, Cohort 1: Partial Oncolysis + SV-102Experimental

Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 1.

Part 1 - Dose Escalation, Cohort 2: Partial Oncolysis + SV-102Experimental

Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 2.

Part 1 - Dose Escalation, Cohort 3: Partial Oncolysis + SV-102Experimental

Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, Dose Level 3.

Part 2 - Dose Optimization, Arm 1: Partial Oncolysis + SV-102Experimental

Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, dose level selected from Part 1.

Part 2 - Dose Optimization, Arm 2: Partial Oncolysis + SV-102Experimental

Participants will receive partial oncolysis plus an intratumoral infusion of SV-102, dose level selected from Part 1.

Procedures: Partial Oncolysis

Drugs: SV-102

Sites

23 sites in 1 country